Castle Biosciences CSTL 深 沪
已收盘 09-11 16:00:00 美东时间
32.33
+0.010
+0.03%
华盛通- 最 高32.94
- 今 开32.77
- 成交量 22.42万股
- 最 低 31.71
- 昨 收 32.32
- 总市值 9.88亿
- 52周最高 44.28
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 17.722
- 委 比 63.78%
- 总股本 3054.95万
- 历史最高 107.69
- 量 比 1.01
- 振 幅 3.81%
- 历史最低 9.2601
- 每 手 1
- 风险率 6.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JAAD Publication Shows Improved Performance of DecisionDx®-SCC
DecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient management DecisionDx...
09-10 04:30
SciBase receives additional order from Castle Biosciences, advancing the collaboration
STOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has rec...
09-08 21:30
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that i...
08-17 19:00
Castle Biosciences Ups 2026 Outlook Amid Growth
Castle Biosciences (($CSTL)) has held its Q2 earnings call. Read on for the mai...
08-10 08:28
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Castle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
Castle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
07-31 04:54
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that i...
07-22 19:00
Castle Biosciences将于7月30日发布第二季度财报并召开网络直播
Castle Biosciences， Inc．宣布，将于2026年7月30日（周四）美股收盘后发布截至2026年6月30日的第二季度财务业绩。公司管理层将...
07-09 21:01
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
